Katsushi Miyake

The 2 nd Survey on the Actual Conditions of Pharmacist Faculties in Pharmacy Schools in Japan

Yukihiro Noda 13, , Ikuko Yano 13, , Takao Aoyama 13, , Michiru Watanabe 13, , Ainari Konda , Hitoshi Nakamura , Ryo Matsushita 13, , Kunihiko Morita , Katsushi Miyake , Hakaru Seo 13, , Naoki Kamimura 13, , Yoshihisa Tomioka 13, , Junko Kizu 13, 14 and Mayumi Mochizuki 14 Faculty of Pharmacy, Meijo University , Graduate School of Pharmaceutical Sciences, Kyoto University , Faculty of Pharmaceutical Sciences, Tokyo University of Science , Faculty of Pharmacy, Musashino University , School of Pharmacy, Hokkaido Pharmaceutical University , Faculty of Pharmaceutical Sciences, Teikyo Heisei University , Faculty of Pharmacy, Institute of Medical, Pharmaceutical and Health Sciences, Kanazawa University , Faculty of Pharmaceutical Sciences, Doshisha Women’s College of Liberal Arts , Faculty of Pharmaceutical Sciences, Hiroshima International University , Faculty of Pharmaceutical Sciences, Sojo University , Graduate School of Pharmaceutical Sciences, Tohoku University , Faculty of Pharmacy, Keio University , Japanese Society of Pharmacist Faculty in Pharmacy Schools 13

The Changes in the Laboratory Values During Administration of Commercially Available Ready-to-use Basal Solutions for Total Parenteral Nutrition

Some differences are seen in the concentrations of glucose and electrolytes between commercially available ready-to-use basal solutions for total parenteral nutrition (R-TPN).In this study, we investigated the effects of the long-term administration of Unicaliq®, which contains relatively higher concentrations of chloride ions than other R-TPNs, on the clinical laboratory values. One hundred and nineteen patients, who received Unicaliq® for more than four weeks at Hiroshima University Hospital, participated in this study. The laboratory values of chloride ion (Cl-) and blood urea nitrogen (BUN) significantly increased after receiving Unicaliq® for 2 weeks, but all levels, except for BUN, returned to the pretreatment levels after 4 weeks of administration. However, these changes were slight and all were within the normal ranges.No changes were observed in other laboratory values during the 4-week administration period.These results suggest that the clinical laboratory values are not affected by the long-term administration of Unicaliq®, at least up until 4 weeks.

Effect of Age on High-Dose Methotrexate Infusion Therapy.

The effect of age on pharmacokinetics of MTX after high-dose MTX (HD-MTX) infusions was investigated. Fifty-nine patients (age: 18-83 years) received HD-MTX infusions (dosage: 1.9-3.8g/m3) for 6 hrs. All patients were divided into the following three groups according to their ages: young group (18-29 years), middle-aged group (31-57 years), and elder group (60-83 years). Mean residence time and clearance of MTX obtained by moment analysis showed a significant delay and decrease, respectively, in the elder group among patients, while there was no significance in the steady-state volume of distribution. In addition, a significantly higher concentration and slower elimination during the first 12 hr were observed in the elder group. Significant resultant decrease in renal and hepatic functions were demonstrated on days 2 and 7, respectively, indicating prompt renal damage and delayed hepatic damage in the elder patients.These results suggest that the pharmacokinetic differences among age groups were evoked by the decreased renal function at the early stage of infusions. Furthermore, drug monitoring in the early stage following the infusion is important for preventing the onset of the severe toxicity common with HD-MTX therapy in the elder patients.

A Case Report on Patient Counseling (1). A Case Study on a Neurosurgery Patient.

The importance of patient counseling has been recognized recently not only by pharmacists but also by other medical staffs and patients. We have started patient counseling from July 1988 on patients and developed to seven clinical departments up to the present. In practicing patient counseling, we attempt to incorporate and to put to practical use not only the drug information but also the data obtained from TDM and clinical tests. Many of the patients being seen at the Clinical Department of Neurosurgery are those who need comprehensive patient counseling involving such as drug information to continuous drug monitoring. In addition to this pharmaceutical basis, one of most important elements is that we have to know well about patients, inclusive of their physical and mental conditions, since these patients are so sensitive and nervous to change unstably.We would like to report a case of patient counseling practice using a patient of our Clinical Department of Neurosurgery as an example case cojoined with TDM and clinical data.